Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPR3 | P17342 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 6/20 | 0.44 |
| ▸ | MMP9 | P14780 | 6/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.44 |
| ▸ | ADAMTS4 | O75173 | 5/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4414181 | 0.87 | NPR3 (0.46) | ALDH1A1MAPTNPR3MMP2MMP9 | |
| SCHEMBL4413818 | 0.87 | MMP2 (0.49) | ALDH1A1MMP2MMP9CTSLCTSS | |
| SCHEMBL7215717 | 0.86 | ALDH1A1 (0.47) | ALDH1A1MAPTNPR3MMP2MMP9 | |
| SCHEMBL7215705 | 0.86 | ALDH1A1 (0.47) | ALDH1A1MAPTNPR3MMP2MMP9 | |
| SCHEMBL31064911 | 0.86 | POLB (0.50) | ALDH1A1MAPTMMP2MMP9ADAMTS4 | |
| SCHEMBL4421322 | 0.85 | ALDH1A1 (0.46) | ALDH1A1MAPTNPR3MMP2MMP9 | |
| Hydrochloric Acid SCHEMBL6504666 | 0.85 | ALDH1A1 (0.46) | ALDH1A1MAPTNPR3MMP2MMP9 | |
| Hydrochloric Acid SCHEMBL6495647 | 0.85 | ALDH1A1 (0.46) | ALDH1A1MAPTNPR3MMP2MMP9 | |
| SCHEMBL4421321 | 0.85 | ALDH1A1 (0.46) | ALDH1A1MAPTNPR3MMP2MMP9 | |
| SCHEMBL6624164 | 0.84 | MMP9 (0.59) | ALDH1A1MAPTNPR3MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313737-B1 | NOVEL GUANIDINO DERIVATIVES AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA GMBH (DE) | 2009-06-03 | — | — | EP | disclosed |
| US-7259159-B2 | Guanidino derivatives as inhibitors of cell adhesion | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-21 | — | — | US | disclosed |
| US-20030203896-A1 | Novel guanidino derivatives as inhibitors of cell adhesion | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-30 | — | — | US | disclosed |
| EP-1313737-A1 | NOVEL GUANIDINO DERIVATIVES AS INHIBITORS OF CELL ADHESION | Aventis Pharma Deutschland GmbH (DE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002010168-A1 | NOVEL GUANIDINO DERIVATIVES AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-02-07 | — | — | WO | disclosed |
| EP-1176145-A1 | Novel guanidino derivatives as inhibitors of cell adhesion | Aventis Pharma Deutschland GmbH (DE) | 2002-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203896-A1 | Novel guanidino derivatives as inhibitors of cell adhesion | ADGRF1, VCAM1, ADGRE5 | ALDH1A1 2768/4885MAPT 4183/4885NPR3 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.